Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Search
BI 706321
BI 706321: Kinase inhibitor
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Boehringer Ingelheim and Fraunhofer partnership
Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
BI 1358894 - PTSD
BI 1358894
Vascular modulator
Vascular modulator
NDMA regulator
NDMA regulator
BI 764198
BI 764198: TRPC6 inhibitor
Avenciguat (BI 685509)
Avenciguat (BI 685509)
Avenciguat (BI 685509)
Avenciguat (BI 685509): sGC activator
STING agonist (2nd generation)
Second generation STING agonist
IL11 antibody
IL11 antibody
BI 764524
BI 764524: Sema3A antibody
BI 1291583
BI 1291583: CatC Inhibitor
Phospholipid modulator
Phospholipid modulator
TREM-1 Antibody
TREM-1 Antibody
Ion channel inhibitor
Ion channel inhibitor
Lysophospholipase inhibitor
Lysophospholipase inhibitor
PD-1 antibody
PD-1 antibody
BI 765845
Heart disease modulator
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio